Jacobson Mark L.'s Form 4 filing
Axsome Therapeutics, Inc.AXSM · filed Jun 10, 2025
- Accession no.
- 0000950170-25-084556
- Filed
- Jun 10, 2025
- Trade date
- Jun 9, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.76M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Jacobson Mark L.CIK 0001805812 | Officer (Chief Operating Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 9, 2025 | Common Stock | MOption exerciseAcquired | +25,000 | $8.02 | +$200,500 | 30,783 | Direct | |
| Jun 9, 2025 | Common Stock | SSaleDisposed | −25,000 | $110.44F4 | −$2,761,000 | 5,783 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 9, 2025 | Common Stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $108.27 and $112.24.
Referenced by the price of 1 transaction in Table I.